Synvisc and Pregnancy
No adequate studies have been performed on Synvisc (hylan G-F 20) and pregnancy, so it is not known whether the treatment is safe for pregnant women. Since the FDA considers Synvisc to be a device, rather than a medication, it does not have a pregnancy category rating. If you become pregnant while receiving Synvisc injections, notify your healthcare provider.
Synvisc® (hylan G-F 20) is a treatment for osteoarthritis that is injected directly into the knee joint. It is not known if the product is safe for use during pregnancy.
The U.S. Food and Drug Administration (FDA) uses a category system to classify the possible risks to a fetus when a specific medicine is taken during pregnancy. However, Synvisc is not considered a medication by the FDA. Instead, it is classified as a device. Therefore, it does not have a pregnancy category rating.
Synvisc has not been adequately studied in pregnant humans, and there does not appear to be any data available from use in pregnant animals either. As a result, the possible negative effects of using this product during pregnancy are not known.
If you are pregnant or thinking about becoming pregnant, let your healthcare provider know. He or she will consider the benefits and risks of taking Synvisc during pregnancy before making a recommendation in your particular situation.